Overview
Clinical Trials of Texas has been recapitalized by NMS Capital to form the new Flourish Research clinical research site platform, to become a nationwide network of clinical research sites with therapeutic area and clinical trial phase diversity.
Significance
The highly fragmented and fast-growing clinical research site industry represents a ~$21B global market; nearly 400,000 studies are conducted annually. With COVID-19 further highlighting the importance of clinical research and trials, the market demands more efficient patient recruitment across a broad range of therapeutic areas and patient populations. This need is driving rapid consolidation in the industry.
Clinical Trials of Texas (CTT) operates a 20,000+ sqft clinical trial “super site” in San Antonio, TX. The company has performed over 1,000 trials across more than 15 therapeutic areas and over 50 indications. Since its founding in 2001, CTT’s focus on patient experience has made them one of the country’s leading research sites, and the ideal platform for NMS Capital to form the new Flourish Research. Flourish Research will become a nationwide network of clinical research sites with therapeutic area and clinical trial phase diversity.
Crosstree’s Role
Crosstree acted as exclusive financial advisor to Clinical Trials of Texas in its recapitalization by NMS Capital through:
- Leveraging market expertise to identify the ideal transaction partner to drive future growth
- Positioning CTT to maximize value
- Driving an outcome for the founder/client well above her expectations
Latest Deals
Myonex Acquired SaveWay Compounding Pharmacy to Expand and Bolster its Clinical Trial Services Across the US
.V3%20(1).png)
Calyx has divested its 'Enterprise Technology' Division to Ennov, to Enhance Ennov’s portfolio of eClinical and eRegulatory Software Solutions
%20(1).png)
physIQ Acquired by Prolaio to Enhance its Next-Gen Connected Heart Care Technology for Clinical Care and Research
.png)
Continuum Clinical, a BC Worldwide company, Acquired by Spectrum Science, a Portfolio Company of Knox Lane, to Bolster Patient Engagement Capabilities
%20(NEW).png)
Yecuris Corporation Acquired by Janvier Group to Expand Preclinical Service Offering Internationally
.png)
Modular Devices, a Portfolio Company of O2 Investment Partners, Partners with Flow Clean Rooms and Supply to Bolster Existing Clean Room Manufacturing Capabilities and Expand Overall Offering
Alpha IRB Acquired by Sabai Global, a Portfolio Company of Thompson Street Capital, to Expand IRB Capabilities
Versiti Acquired Pearl Pathways to Expand Clinical Trial Services Capabilities
VaxTRIALS Acquired by Emmes, a portfolio company of New Mountain Capital, to Expand Vaccine and Clinical Trial Site Capabilities
Grant Avenue Capital Recapitalizes CREO
Monroe Biomedical Research Acquired by New Harbor Capital in a First Step to Build-out a Clinical Research Site Platform
SSI Strategy, a Portfolio Company of Amulet Capital Partners, Acquired NDA Group AB to Bolster Regulatory Affairs Consulting Capabilities and Expand Into the EU
Catalyst Clinical Research, a Portfolio Company of QHP Capital, Acquired Genpro Research to Expand Global Footprint and Deepen Service Offerings
Accel Research Sites Network Acquired by Alcanza Clinical Research, a portfolio company of Martis Capital, to Expand its Clinical Trial Site Network and Clinical Trial Execution Capabilities
Benchmark Research Acquired by IQVIA, combined with Avacare to Expand Vaccine and Clinical Trial Site Capabilities
Clinical Site Services and Patient Advertising Guru Acquired by American Clinical Research Services to Add Tech-Enabled Patient Recruitment Capabilities
ClinChoice Acquires CROMSOURCE to Expand CRO Capabilities Globally
anteris Acquired by Kymanox, a Portfolio Company of Westview Capital Partners, to Expand Injectable Combination Product Development Capabilities Globally
OpenClinica Completes Growth Recapitalization with Thompson Street Capital Partners to Accelerate Enablement of Clinical Trials
